This surge is also being driven by India's cost advantages compared to Western countries, 90 per cent faster project startup ...

Our Bureau, Bengaluru Tuesday, February 25, 2025, 15:15 Hrs [IST] ...

Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 ...